Live Breaking News & Updates on Episteme Prognostics
Stay updated with breaking news from Episteme prognostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In 2001, when Phil Ferneau and his partners were launching a venture capital firm focused on New Hampshire startups, they met with several academics at Dartmouth College. Ferneau had been an advocate for converting academic research into viable. ....
In 2001, when Phil Ferneau and his partners were launching a venture capital firm focused on NH startups, they met with several academics at Dartmouth College. Ferneau had been an advocate for converting academic research into viable companies in his. ....
LEBANON There are cancers, and there are worse cancers. Then there is pancreatic cancer.This year 60,000 people will be diagnosed with pancreatic cancer, according to the American Cancer Society, and 48,000 will die from the disease, an 80%. ....
(L-R) Dartmouth and Dartmouth-Hitchcock s Norris Cotton Cancer Center (NCCC) Director Steven D. Leach, MD, and Surajit Dhara, PhD, Senior Research Scientist, working together in the Leach laboratory at NCCC to bring change to the treatment of pancreatic cancer with new technology. By 2030, the most lethal form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is projected to become the second leading cause of cancer-related deaths in the United States. Not only are therapeutic options limited, but nearly half of PDAC patients who have their tumors removed surgically experience disease recurrence within a year, even with chemotherapy. For more advanced stages, approximately one-third of patients have a limited response to chemotherapy. ....
Researchers are developing first prognostic, therapeutic epigenetic biomarker for pancreatic cancer patients By 2030, pancreatic ductal adenocarcinoma (PDAC), the most lethal form of pancreatic cancer, is projected to become the second leading cause of cancer-related deaths in the United States. Not only are therapeutic options limited, but nearly half of all PDAC patients who have their tumors removed surgically experience disease recurrence within a year, despite receiving additional chemotherapy. For more advanced stages, only about one-third of patients have a limited response to approved chemotherapy. A team of researchers led by Dartmouth and Dartmouth-Hitchcock s Norris Cotton Cancer Center (NCCC) Director Steven D. Leach, MD, and Surajit Dhara, PhD, Senior Research Scientist in the Leach laboratory, in collaboration with colleagues at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, are developing the first prognostic and therapeutic epigeneti ....